Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) major shareholder Life Sciences Maste Perceptive acquired 296,007 shares of Aldeyra Therapeutics stock in a transaction that occurred on Friday, June 30th. The stock was acquired at an average price of $4.60 per share, with a total value of $1,361,632.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Aldeyra Therapeutics, Inc. (NASDAQ ALDX) opened at 4.85 on Tuesday. Aldeyra Therapeutics, Inc. has a 1-year low of $3.80 and a 1-year high of $8.19. The company’s market capitalization is $30.29 million. The firm’s 50 day moving average price is $4.63 and its 200-day moving average price is $4.87.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. Analysts expect that Aldeyra Therapeutics, Inc. will post ($1.58) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Life Sciences Maste Perceptive Acquires 296,007 Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Stock” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/18/life-sciences-maste-perceptive-acquires-296007-shares-of-aldeyra-therapeutics-inc-nasdaqaldx-stock-updated.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter valued at about $132,000. Hikari Power Ltd purchased a new position in shares of Aldeyra Therapeutics during the first quarter valued at about $188,000. Sabby Management LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter valued at about $898,000. Sphera Funds Management LTD. boosted its position in shares of Aldeyra Therapeutics by 81.4% in the first quarter. Sphera Funds Management LTD. now owns 668,500 shares of the biotechnology company’s stock valued at $3,343,000 after buying an additional 300,000 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in shares of Aldeyra Therapeutics by 48.7% in the first quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after buying an additional 945,000 shares during the last quarter. Hedge funds and other institutional investors own 58.25% of the company’s stock.
Several equities research analysts recently commented on ALDX shares. Cowen and Company reiterated a “buy” rating and issued a $20.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, March 31st. Stifel Nicolaus reiterated a “buy” rating and issued a $16.00 price objective on shares of Aldeyra Therapeutics in a report on Wednesday, May 31st. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 30th. HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $12.00 price objective (down from $15.00) on shares of Aldeyra Therapeutics in a report on Friday, March 31st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aldeyra Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.30.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.